

Elicitation of lead compounds for the treatment of chronic obstructive pulmonary disease targeting leucotriene B4 receptor BLT2

Korea University



RESPIRATORY	Lead
Product Type	Small molecule / Chemical product
Indication	1st: Chronic obstructive pulmonary disease (COPD) exacerbation 2nd: Severe asthma – Non Th2 – Neutrophilic asthma
Target	Chemoattractant leukotriene B4 receptor 2 (BLT2)
MoA(Mechanism of Action)	By inhibiting the action of LTB4-BLT2 and regulating the activity of neutrophils gathered in the airways, it improves airway smooth muscle remodeling commonly found in COPD and severe asthma
Competitiveness	First in class Currently prescribed treatments are bronchodilators and steroids, but they are symptom reliever, not fundamental treatment. IL-5 antibody, P38 α antibody and PDE4 inhibitors are under development. However, there are side effects and problems with efficacy.
Development Stage	Lead
Route of Administration	Oral administration